Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

Frontiers in Pharmacology
Eduardo Ekman Schenberg

Abstract

Mental disorders are rising while development of novel psychiatric medications is declining. This stall in innovation has also been linked with intense debates on the current diagnostics and explanations for mental disorders, together constituting a paradigmatic crisis. A radical innovation is psychedelic-assisted psychotherapy (PAP): professionally supervised use of ketamine, MDMA, psilocybin, LSD and ibogaine as part of elaborated psychotherapy programs. Clinical results so far have shown safety and efficacy, even for "treatment resistant" conditions, and thus deserve increasing attention from medical, psychological and psychiatric professionals. But more than novel treatments, the PAP model also has important consequences for the diagnostics and explanation axis of the psychiatric crisis, challenging the discrete nosological entities and advancing novel explanations for mental disorders and their treatment, in a model considerate of social and cultural factors, including adversities, trauma, and the therapeutic potential of some non-ordinary states of consciousness.

References

Apr 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H D AbrahamP Gogia
Apr 1, 1997·Journal of Psychoactive Drugs·E M Krupitsky, A Y Grinenko
Apr 1, 1997·Journal of Psychoactive Drugs·B Eisner
Nov 14, 2001·The Alkaloids. Chemistry and Biology·K R Alper
Aug 10, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Erika Dyck
Jun 20, 2006·The Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry·Eric M Plakun
May 26, 2007·Journal of Psychoactive Drugs·Evgeny M KrupitskyAlexander Y Grinenko
Jul 3, 2008·Journal of Psychopharmacology·Mw JohnsonRr Griffiths
Nov 14, 2008·Journal of Psychoactive Drugs·José Carlos BousoGregorio Gómez-Jarabo
Dec 2, 2008·CNS Neuroscience & Therapeutics·Torsten PassieAnnelie Hintzen
Oct 7, 2009·Addiction·Neeltje VogelsRaymond J M Niesink
Jan 6, 2010·Archives of General Psychiatry·Ramin Mojtabai, Mark Olfson
Jun 1, 2010·Lancet·Barbara J SahakianUNKNOWN Mental Health Review Group
Jul 31, 2010·Science·Greg Miller
Aug 19, 2010·Nature Reviews. Neuroscience·Franz X Vollenweider, Michael Kometer
Aug 21, 2010·Emergency Medicine Journal : EMJ·David Michael WoodJohn Ramsey
Sep 8, 2010·Archives of General Psychiatry·Charles S GrobGeorge R Greer
Nov 3, 2010·Lancet·David J NuttUNKNOWN Independent Scientific Committee on Drugs
Jan 25, 2011·Regulatory Toxicology and Pharmacology : RTP·Jan van AmsterdamWim van den Brink
Jun 10, 2011·British Journal of Clinical Pharmacology·Joop van Gerven, Adam Cohen
Jun 16, 2011·Psychopharmacology·Roland R GriffithsRobert Jesse
Oct 1, 2011·Journal of Psychopharmacology·Katherine A MacLeanRoland R Griffiths
Dec 2, 2011·Drug and Alcohol Dependence·Matthew W JohnsonRoland R Griffiths
Jan 17, 2012·Neuron·David E J Linden
Jan 25, 2012·Journal of Forensic Sciences·Kenneth R AlperJames R Gill
Mar 13, 2012·Journal of Psychopharmacology·Teri S Krebs, Pål-Ørjan Johansen
Mar 31, 2012·Addiction Biology·Xaver KoenigKarlheinz Hilber
Jul 13, 2012·Biological Psychiatry·Michael H BlochChristopher Pittenger
Jan 29, 2013·Neuropsychiatric Disease and Treatment·Goran MedicRené S Kahn
Apr 27, 2013·Nature·David Adam
May 1, 2013·Current Drug Abuse Reviews·Thomas Kingsley Brown
May 7, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ferrán Catalá-LópezRafael Tabarés-Seisdedos
May 17, 2013·Mens Sana Monographs·Sanjay KukrejaAmresh Shrivastava
Jun 13, 2013·Nature Reviews. Neuroscience·David J NuttDavid E Nichols
Jun 21, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Carolyn I RodriguezHelen B Simpson
Jul 25, 2013·Current Opinion in Psychiatry·Sarah C E Chapman, Rob Horne
Aug 27, 2013·PloS One·Teri S Krebs, Pål-Ørjan Johansen
Sep 21, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Suresh D MuthukumaraswamyDavid J Nutt
Oct 19, 2013·Nature Reviews. Neuroscience·B J CaseyKerry J Ressler
Dec 19, 2013·The International Journal of Neuropsychopharmacology·R L Carhart-HarrisD J Nutt

❮ Previous
Next ❯

Citations

Mar 7, 2019·Journal of Psychoactive Drugs·Jacob S AdayChristopher C Davoli
Jul 16, 2019·Journal of Psychopharmacology·Kim Pc KuypersDavid Nutt
Jul 12, 2019·Journal of Psychopharmacology·Leor RosemanRobin Carhart-Harris
Jan 11, 2020·General Psychiatry·Eric BuiAndrew Melaragno
Feb 23, 2020·PloS One·Bheatrix BienemannDaniel C Mograbi
Jun 2, 2020·Expert Review of Clinical Pharmacology·Kyle T GreenwayAllison A Feduccia
Jul 9, 2020·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Alvaro V JardimEduardo E Schenberg
Jul 17, 2020·Brain Communications·Caitlin DaviesEmily N W Wheater
Sep 29, 2020·Journal of Psychoactive Drugs·Matteo PolitiJaime Torres
Dec 7, 2020·Pharmacology Research & Perspectives·Benjamin StewartVikas Kotagal
Nov 20, 2020·European Journal of Clinical Pharmacology·Paul GlueNatalie J Medlicott
Mar 31, 2021·Journal of Psychopharmacology·Rachael L SumnerFrederick Sundram
Apr 9, 2021·Harm Reduction Journal·Brian PileckiVilmarie Fraguada Narloch
Jun 22, 2021·Frontiers in Pharmacology·David M O'Shaughnessy, Ilana Berlowitz
Jul 3, 2021·International Journal of Environmental Research and Public Health·Radosław Stupak, Bartłomiej Dobroczyński
Jul 31, 2021·Frontiers in Psychology·Sascha B ThalPetra M Skeffington
Sep 15, 2018·ACS Chemical Neuroscience·Michael J WaskoChristopher K Surratt

❮ Previous
Next ❯

Software Mentioned

PAP

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Psychotherapy
S M SCHOEN
Journal of Psychopharmacology
Guy M Goodwin
Nursing Times
R A SANDISON, I HOPKIN
© 2022 Meta ULC. All rights reserved